Multimedica S.p.A.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
Multimedica S.p.A. conducts research aimed at improving outcomes for patients with cardiovascular disease, including hypertension and heart failure, often in conjunction with respiratory conditions. Trials assess the safety and effectiveness of novel combination therapies and explore how pulmonary treatments impact heart health.
- Hypertension management strategies
- Heart failure and cardiopulmonary outcomes
- Cardiovascular safety of inhaled medications
- Combination therapy to reduce cardiovascular events
The multidisciplinary team collaborates closely with cardiology specialists to ensure patient‑centered care and robust data collection across both heart and lung domains.
Eye Diseases
The site’s ophthalmology program evaluates innovative treatments for dry eye disease, age‑related macular degeneration, and inflammatory ocular conditions such as atopic keratoconjunctivitis. Studies aim to restore visual function, slow lesion growth, and improve patient‑reported comfort.
- Dry eye disease therapeutic trials
- Geographic atrophy and macular degeneration studies
- Atopic keratoconjunctivitis management
- Polypoidal choroidal vasculopathy interventions
Advanced imaging and patient‑reported outcome measures support the development of next‑generation ocular drugs at Multimedica.
Neoplasms
Research at Multimedica also encompasses neoplastic conditions, focusing on the intersection of cancer and systemic health. Trials investigate targeted agents, safety profiles, and the impact of comorbid respiratory disease on cancer therapy effectiveness.
- Targeted therapies for ocular and systemic tumors
- Biomarker studies in cancer patients with lung disease
- Safety evaluation of anti‑angiogenic drugs
- Combination regimens for patients with cardiovascular risk
Collaboration with oncology experts ensures rigorous assessment of novel treatments while prioritizing patient safety.
Respiratory Tract Diseases
The core of Multimedica’s clinical research portfolio addresses respiratory tract diseases, including Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis, pulmonary arterial hypertension, and progressive fibrosing interstitial lung disease. Trials test inhaled therapies, antifibrotic agents, and combination regimens to improve lung function and quality of life.
- Chronic Obstructive Pulmonary Disease
- Idiopathic Pulmonary Fibrosis and related fibrosing ILDs
- Pulmonary arterial hypertension
- Progressive pulmonary fibrosis
- Nontuberculous mycobacterial lung infection
- Pulmonary sarcoidosis
Long‑term follow‑up studies evaluate safety, tolerability, and functional outcomes, providing valuable insights for patients and clinicians alike.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 44 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 16 by active trials.
lock +15 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +9 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Multimedica S.p.A.
lock Showing 1 of 42 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallelgroup Study to Evaluate the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease | Insmed Inc. | Phase III | Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 44 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Sotatercept | 4 | Unknown | 2021-08-26 | 2025-12-19 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.